CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications
US7173046B2 · kind B2 · utility
7Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2003 |
| Grant date | Feb 6, 2007 |
| Priority date | — |
| Expiry date | Feb 28, 2023 |
Classification
- Technology area (CPC F)Mechanical Engineering; Lighting; Heating
- CPC primaryF25B2309/14241
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.